Non-invasive molecular and functional imaging of cytosine deaminase and uracil phosphoribosyltransferase fused with red fluorescence protein

Acta Oncologica

Volumn 47, Issue 7, 2008, Pages 1211-1220

  Xing, Ligang ^a   Deng, Xuelong ^a   Kotedia, Khushali ^a   Ackerstaff, Ellen ^a   Ponomarev, Vladimir ^a   Ling, C Clifton ^a   Koutcher, Jason A ^a   Li, Gloria C ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOSINE DEAMINASE; FLUCYTOSINE; FLUORONUCLEOTIDE DERIVATIVE; FLUOROURACIL; HYBRID PROTEIN; NUCLEOTIDE DERIVATIVE; RED FLUORESCENT PROTEIN; UNCLASSIFIED DRUG; URACIL PHOSPHORIBOSYLTRANSFERASE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER CELL CULTURE; CELL STRAIN COS7; CELL SURVIVAL; CONTROLLED STUDY; CYTOTOXICITY; DRUG METABOLISM; FLOW CYTOMETRY; FLUORESCENCE MICROSCOPY; IN VITRO STUDY; IN VIVO STUDY; MALE; MOLECULAR IMAGING; MOUSE; NONHUMAN; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; PRIORITY JOURNAL; PROSTATE CARCINOMA; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN PROTEIN INTERACTION; RAT; TUMOR XENOGRAFT; WESTERN BLOTTING;

ANIMALS; BLOTTING, WESTERN; CELL LINE, TUMOR; CYTOSINE DEAMINASE; FLOW CYTOMETRY; FLUORINE RADIOISOTOPES; GENES, REPORTER; LUMINESCENT PROTEINS; MAGNETIC RESONANCE SPECTROSCOPY; MALE; MICE; MICE, NUDE; PENTOSYLTRANSFERASES; PROSTATIC NEOPLASMS; RATS; SENSITIVITY AND SPECIFICITY; TRANSFECTION; TRANSGENES;

EID: 51049113198     PISSN: 0284186X     EISSN: 1651226X     Source Type: Journal    
DOI: 10.1080/02841860802256475     Document Type: Article

References (26)

1. Greco O, Dachs GU. Gene directed enzyme/prodrug therapy of cancer: Historical appraisal and future prospectives. J Cell Physiol 2001;187:22-36.
2. Crystal RG, Hirschowitz E, Lieberman M, Daly J, Kazam E, Henschke C, et al. Phase I study of direct administration of a replication deficient adenovirus vector containing the E. coli cytosine deaminase gene to metastatic colon carcinoma of the liver in association with the oral administration of the pro-drug 5-fluorocytosine. Hum Gene Ther 1997;8:985-1001.
3. Pandha HS, Martin LA, Rigg A, Hurst HC, Stamp GW, Sikora K, et al. Genetic prodrug activation therapy for breast cancer: A phase I clinical trial of erbB-2-directed suicide gene expression. J Clin Oncol 1999;17:2180-9.
4. Daher GC, Harris BE, Diasio RB. Metabolism of pyrimidine analogues and their nucleosides. Pharmacol Ther 1990;48:189-222.
5. Kanai F, Kawakami T, Hamada H, Sadata A, Yoshida Y, Tanaka T, et al. Adenovirus-mediated transduction of Escherichia coli uracil phosphoribosyltransferase gene sensitizes cancer cells to low concentrations of 5-fluorouracil. Cancer Res 1998;58:1946-51.
6. Tiraby M, Cazaux C, Baron M, Drocourt D, Reynes JP, Tiraby G. Concomitant expression of E. coli cytosine deaminase and uracil phosphoribosyltransferase improves the cytotoxicity of 5-fluorocytosine. FEMS Microbiol Lett 1998;167:41-9.
7. Erbs P, Regulier E, Kintz J, Leroy P, Poitevin Y, Exinger F, et al. In vivo cancer gene therapy by adenovirus-mediated transfer of a bifunctional yeast cytosine deaminase/uracil phosphoribosyltransferase fusion gene. Cancer Res 2000;60:3813-22.
8. Tjuvajev JG, Stockhammer G, Desai R, Uehara H, Watanabe K, Gansbacher B, et al. Imaging the expression of transfected genes in vivo. Cancer Res 1995;55:6126-32.
9. Gade TP, Koutcher JA, Spees WM, Beattie BJ, Ponomarev V, Doubrovin M, et al. Imaging transgene activity in vivo. Cancer Res 2008;68:2878-84.
10. Golzio M, Rols MP, Gabriel B, Teissie J. Optical imaging of in vivo gene expression: A critical assessment of the methodology and associated technologies. Gene Ther 2004;11(Suppl 1):S85-91.
11. Jacobs A, Dubrovin M, Hewett J, Sena-Esteves M, Tan CW, Slack M, et al. Functional coexpression of HSV-1 thymidine kinase and green fluorescent protein: Implications for noninvasive imaging of transgene expression. Neoplasia 1999;1:154-61.
12. Steffens S, Frank S, Fischer U, Heuser C, Meyer KL, Dobberstein KU, et al. Enhanced green fluorescent protein fusion proteins of herpes simplex virus type 1 thymidine kinase and cytochrome P450 4B1: Applications for prodrug-activating gene therapy. Cancer Gene Ther 2000;7:806-12.
13. Baird GS, Zacharias DA, Tsien RY. Biochemistry, mutagenesis, and oligomerization of DsRed, a red fluorescent protein from coral. Proc Natl Acad Sci U S A 2000;97:11984-9.
14. Campbell RE, Tour O, Palmer AE, Steinbach PA, Baird GS, Zacharias DA, et al. A monomeric red fluorescent protein. Proc Natl Acad Sci U S A 2002;99:7877-82.
15. Muller-Taubenberger A, Vos MJ, Bottger A, Lasi M, Lai FP, Fischer M, et al. Monomeric red fluorescent protein variants used for imaging studies in different species. Eur J Cell Biol 2006;85:1119-29.
16. Wolf W, Waluch V, Presant CA. Non-invasive 19F-NMRS of 5-fluorouracil in pharmacokinetics and pharmacodynamic studies. NMR Biomed 1998;11:380-7.
17. Naser-Hijazi B, Berger MR, Schmahl D, Schlag P, Hull WE. Locoregional administration of 5-fluoro-2′-deoxyuridine (FdUrd) in Novikoff hepatoma in the rat: effects of dose and infusion time on tumor growth and on FdUrd metabolite levels in tumor tissue as determined by 19F-NMR spectroscopy. J Cancer Res Clin Oncol 1991;117:295-304.
18. Stegman LD, Rehemtulla A, Beattie B, Kievit E, Lawrence TS, Blasberg RG, et al. Noninvasive quantitation of cytosine deaminase transgene expression in human tumor xenografts with in vivo magnetic resonance spectroscopy. Proc Natl Acad Sci U S A 1999;96:9821-6.
19. Hamstra DA, Lee KC, Tychewicz JM, Schepkin VD, Moffat BA, Chen M, et al. The use of 19F spectroscopy and diffusion-weighted MRI to evaluate differences in genedependent enzyme prodrug therapies. Mol Ther 2004;10:916-28.
20. He F, Li L, Kim D, Wen B, Deng X, Gutin PH, et al. Adenovirus-mediated expression of a dominant negative Ku70 fragment radiosensitizes human tumor cells under aerobic and hypoxic conditions. Cancer Res 2007;67:634-42.
21. Procissi D, Claus F, Burgman P, Koziorowski J, Chapman JD, Thakur SB, et al. In vivo 19F magnetic resonance spectroscopy and chemical shift imaging of tri-fluoronitroimidazole as a potential hypoxia reporter in solid tumors. Clin Cancer Res 2007;13:3738-47.
22. Muruganandham M, Alfieri AA, Matei C, Chen Y, Sukenick G, Schemainda I, et al. Metabolic signatures associated with a NAD synthesis inhibitor-induced tumor apoptosis identified by 1H-decoupled-31P magnetic resonance spectroscopy. Clin Cancer Res 2005;11:3503-13.
23. Stevens AN, Morris PG, Iles RA, Sheldon PW, Griffiths JR. 5-fluorouracil metabolism monitored in vivo by 19F NMR. Br J Cancer 1984;50:113-7.
24. Schlemmer HP, Bachert P, Semmler W, Hohenberger P, Schlag P, Lorenz WJ, et al. Drug monitoring of 5-fluorouracil: in vivo 19F NMR study during 5-FU chemotherapy in patients with metastases of colorectal adenocarcinoma. Magn Reson Imaging 1994;12:497-511.
25. Koyama F, Sawada H, Hirao T, Fujii H, Hamada H, Nakano H. Combined suicide gene therapy for human colon cancer cells using adenovirus-mediated transfer of escherichia coli cytosine deaminase gene and Escherichia coli uracil phosphoribosyltransferase gene with 5-fluorocytosine. Cancer Gene Ther 2000;7:1015-22.
26. Kievit E, Bershad E, Ng E, Sethna P, Dev I, Lawrence TS, et al. Superiority of yeast over bacterial cytosine deaminase for enzyme/prodrug gene therapy in colon cancer xenografts. Cancer Res 1999;59:1417-21.